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Abstract: Combination antiretroviral therapy for HIV-1 infection has resulted in profound 
reductions  in  viremia  and  is  associated  with  marked  improvements  in  morbidity  and 
mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug 
toxicity  and  the emergence of drug  resistance.  Management of clinical drug resistance 
requires  in  depth  evaluation,  and  includes  extensive  history,  physical  examination  and 
laboratory  studies.  Appropriate  use  of  resistance  testing  provides  valuable  information 
useful  in  constructing  regimens  for  treatment-experienced  individuals  with  viremia  
during  therapy.  This  review  outlines  the  emergence  of  drug  resistance  in  vivo,  and 
describes  clinical  evaluation  and  therapeutic  options  of  the  individual  with  rebound 
viremia during therapy. 
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1. Introduction 
Combination antiretroviral therapy has resulted in marked improvements in morbidity and mortality 
from  HIV-1  infection  [1–3].  Therapy  is  not  curative,  however,  and  one  of  the  most  profound 
limitations of current antiretroviral therapy is the development of antiviral drug resistance [4]. HIV 
drug resistance occurs in a substantial proportion of treated patients and accumulates over time on 
therapy.  Although  the  frequency  of  drug  resistance  has  declined  with  the  introduction  of  better 
tolerated regimens, resistance is still reported in 7–15% of patients initiating first line antiretroviral 
therapy [5–7]. Emergence of drug resistance has consequences for individuals and populations. For 
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individuals,  drug  resistance  restricts  subsequent  antiretroviral  treatment  choices  and  can  exhaust 
therapeutic options, resulting in HIV-1 disease progression and death. Drug-resistant variants are also 
transmitted  when  new  infections  occur,  effectively  multiplying  the  individual  drug  failures  and 
creating  a  growing  public  health  concern.  Surveillance  studies  report  that  the  prevalence  of  
drug-resistant mutations among recently infected drug-naïve individuals ranges from ca. 5–15% [8]. 
As such, transmission of drug resistance threatens to reverse the reductions in morbidity and mortality 
accomplished  by  antiretroviral  therapy.  Emergence  of  drug  resistance  is  a  consequence  of  a 
combination of viral, pharmacologic, and host factors. Identification, evaluation, and treatment of HIV 
drug  resistance  represent  a  compelling  challenge  for  patients  and  health  care  professionals. 
Management of clinical resistance is a comprehensive process that determines the cause of rebound 
viremia and develops a useful course designed to re-suppress HIV replication. In this review we will 
describe factors in the development of drug resistance, and current issues in the clinical management 
of HIV drug resistance in vivo.  
2. Sources of Drug Resistance 
Since the development of antiretroviral therapy, over 20 chemotherapeutic agents have been FDA 
approved. Therapy is been directed against five principal viral targets, including attachment, fusion, 
reverse  transcription,  integration,  and  protease  mediated  maturation.  Regardless  of  drug  target, 
resistance may emerge to any antiretroviral, and viral, pharmacologic, and host factors contribute to 
the emergence of drug resistance. The replication program of HIV is rapid (T1/2 approximately 1 day) 
and error prone (mutation rate ca. 3 × 10
−5 mutations/base/replication cycle) resulting in large and 
genetically diverse populations in vivo from which resistance may emerge [9]. Analysis of kinetics of 
emergence of drug resistance in vivo suggested that many single nucleotide mutations conferring drug 
resistance might be present prior to initiation of antiretroviral therapy. Early studies demonstrating 
rapid emergence of the single nucleotide mutations M184I and M184V resistance to 3TC suggested 
that  therapy  represents  a  selective  pressure  permitting  emergence  of  resistant  variants  [10–12].  
Pre-existing resistance is strongly supported by subsequent studies demonstrating the rapid, frequent 
emergence of drug resistance mutations after single dose of the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) nevirapine [13]. Direct identification of drug resistance mutations pre-therapy has 
also  been  reported  using  sensitive  allele-specific  PCR  amplification  capable  of  detecting  drug 
resistance at levels of ca. 0.3% [14]. 
Reverse transcriptase strand transfer events occur during reverse transcription. These events result 
in  frequent  recombination  and  as  many  as  6–7  strand  transfers  may  take  place  during  proviral 
synthesis. Reverse transcription and recombination of virions containing non-identical RNA copies 
encoding different individual resistance profiles will result in chimeric proviral DNA molecules with 
concatenated  individual  resistance  mutations  [15].  As  a  consequence,  recombination  is  a  potent 
mechanism for rapid spread of drug resistance mutations within an individual. Pharmacologic factors 
contribute to the development of resistance. In general, antiretroviral drugs are well absorbed and 
generate  high  drug  levels  capable  of  inhibiting  HIV  replication.  Several  agents,  specifically  the 
NNRTI class, have long half lives relative to the other regimen components. During non-adherent 
periods, short half life agents are eliminated relatively quickly, while longer agents become essentially Viruses 2011, 3                         
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monotherapeutic  agents,  which  can  select  for  drug  resistance.  Individuals  taking  antiretroviral 
medications often take additional therapeutic agents for co-morbid illnesses; drug interactions may 
result in changes in antiretroviral drug levels [16,17]. Although ongoing therapeutic drug monitoring 
has  not  become  a  clinic  routine  [18,19], drug level testing for all FDA approved antiretroviral is 
available and may be useful in evaluating whether sufficient drug levels are achieved, especially in 
individuals taking complex multidrug regimens to treat HIV and other illnesses, where drug interaction 
issues may arise.  
Host  factors,  principally  drug  adherence,  have  a  strong  effect  on  the  development  of  drug 
resistance. Early studies of antiretroviral therapy demonstrated frequent emergence of resistance to 
antiretroviral agents; regimens were complex, required frequent dosing, and were associated with a 
number  of  adverse  effects;  therapy  interruption  was  relatively  common,  and  rapidly  resulted  in 
development of drug  resistance.  With newer  and  better  tolerated  combination regimens, including 
those with once daily dosing, adherence generally improved in individuals taking first line regimens, 
and  drug  regimen  failures  have  declined.  Nevertheless,  adherence  remains  a  central  issue  in  the 
development  of  resistance  [3,20,21].  Direct  observed  therapy  has  been  useful  in  investigating  the 
virologic and immunologic effects of rigorously controlled drug delivery, although questions remain 
regarding the degree of improvement over voluntary therapy [22] and the content of care used to 
address adherence can predict virologic suppression [23]. Recent studies have suggested that the effect 
of nonadherence is not uniform [3], and that the probability of rebound viremia with non-adherence 
may decrease after viral suppression is achieved. A study from the REACH cohort studied 221 patients 
initiating antiretroviral therapy and estimated the probability of rebound viremia for various ranges of 
adherence after viral suppression is achieved. The probability of virologic failure after 1 month vs. 12 
months  of  continuous  HIV  suppression  with  50–74%  adherence  was  0.47,  and  0.36  at  90–100% 
adherence [24]. In independent studies, Bello and colleagues [25] investigated the level of viremia 
associated  with  long-term  suppression;  viremia  >  100  copies/mL  plasma  were  associated  with 
accumulation of new genetic diversity over time while little or no evidence was detected at lower viral 
RNA levels. The development of once daily regimens and combination formulation of antiretrovirals 
represent great improvements in therapy, making HIV therapy similar to therapy for other chronic 
diseases requiring daily therapy, such as therapy for hypertension, diabetes, and seizure disorders. 
Adherence  to  therapy  for  these  other  illnesses  also  presents  a  number  of  challenges;  behavioral 
research in these diverse areas may yield new and useful strategies to improve adherence. 
With the observations that HIV persists during therapy, it has become clear that understanding the 
nature of HIV replication during therapy has direct bearing on the potential for the emergence of drug 
resistance during therapy. If active spreading infection of HIV continues during drug suppression, then 
the potential for new mutations and drug resistance is possible. Alternatively, if drug suppression 
completely blocks spreading infection, the potential for emergence of new drug resistance mutations 
from chronically infected, long lived reservoirs is severely limited. Seminal studies by Persaud and 
coworkers  demonstrated  no  emergence  of  new  drug  resistance  mutations  on  therapy  [26],  while 
Martinez-Picardo and coworkers did identify emergence of mutations in individuals with prior therapy 
and transient viremic periods [27]. Subsequently, data supporting the presence and absence of active 
replication during therapy have been reported, reviewed by [28]. In a set of interventional studies, drug 
intensification  has  been  used  as  a  strategy  to  investigate  whether  ongoing  replication  takes  place Viruses 2011, 3                         
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during  suppressive  antiretroviral  therapy,  reviewed  by  Maldarelli  [29];  a  number  of  studies  have 
detected  no  evidence  of decreased  viremia during drug  intensification using sensitive single  copy 
detection assays. Buzon and colleagues [30] have identified patients with increased levels of 2-LTR 
circular  DNA  during  raltegravir  intensification,  suggesting  that,  in  some  patients,  residual  HIV 
replication may be present. Research to confirm these findings and to characterize patients undergoing 
antiretroviral therapy with complete suppression or ongoing replication continues. 
Host genetic variation can have strong effects on the course of HIV infection. There are strong host 
encoded differences in the rate of metabolism of antiretrovirals; such pharmacogenomic issues can 
contribute to drug half life, and may result in underexposure leading to resistance, or over-exposure 
leading to toxicity of antiretrovirals [31]. In addition, specific host traits, such as HLA, have direct 
effect on development of cutaneous hypersensitivity to drugs including the antiretroviral abacavir [32]. 
Research  in  this  areas  continues  to  expand  to  include  genome  wide  understanding  of  host-virus 
interactions.  
2.1. Laboratory methods for detection of antiviral drug resistance  
2.1.1. Genotyping 
Genotyping identifies resistance by a three step process of (1) nucleic acid analysis of relevant 
portions  of the HIV genome  derived from plasma, (2) identifying mutations associated with drug 
resistance, (3) constructing a drug resistance report. Nucleic acid analysis consists of extraction of HIV 
RNA  from  plasma,  reverse  transcription  and  PCR  amplification  of  relevant  portions  of  the  HIV 
genome. HIV has broad genetic diversity that is lost, to a significant degree, during the amplification 
process; as a consequence only the most common variants (present in at least 15–20%) are represented 
in  the  genotypic  information  provided  to  the  health  care  professional  and  the  patient.  Resistance 
associated mutations are typically “archived” in cells for apparently indefinite periods. Thus, it is 
possible that drug resistance may be present in the individual with rebound viremia on therapy but not 
detectable in resistance assays. Direct nucleic acid sequencing represents a common mechanism to 
obtain resistance information; commercial genotyping services, as well as systems for laboratory use 
are  available; routine testing with independent panels of resistant viruses is useful to maintaining 
proficiency in detection of mutations [33–35]. Assays for specific mutations by selective hybridization 
are also available commercially in selected parts of the world; such “line probe” assays are reported to 
be more sensitive for detection of low level mutations, but are limited by the number of mutations 
available for assay [36–38]. It is possible that natural genetic variation surrounding the mutation site 
may  affect  detection  of  mutations.  Mutations  are  identified  by  comparison  with  HIV  “wild  type” 
sequences. In the setting of wide genetic diversity “wild type” HIV is certainly only an approximation; 
commercially,  laboratory  infectious  clones,  such  as  pNL4-3  [39]  or  LAV  [40]  are  used  as 
representative viruses. Drug resistance sites have been identified  in vivo and in vitro. In vivo, the 
emergence of specific changes on rebound viremia during therapy are identified and studied in vitro, 
demonstrating that introduction of specific mutations into wild type (WT) virus recapitulates drug 
resistance. In vitro cultivation studies also identify drug resistance mutations, typically with gradual 
emergence  of  resistance  during  long-term  passage  of  HIV  in  the  presence  of  antiretrovirals.  The 
combination  of  in  vivo  and  in  vitro  studies  has  yielded  a  comprehensive  list  of  drug  resistance Viruses 2011, 3                         
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mutations  [35].  Commercial  genotyping  report  provides  the  list  of  mutations  conferring  drug 
resistance, and also synthesizes the genotypic information into an interpretation provided to the health 
care professional, reporting predicted resistance for each drug. The predictions are either rule based, or 
the product of algorithms derived by analyses of large proprietary databases; all are detailed, but none 
are perfect [41,42]. The algorithms and rules are regularly updated with new accumulated data; new 
mutations may be added while others may be dropped. In addition, a number of public access sites 
(e.g., Stanford University HIV Drug Resistance Database [43]) are available to analyze genotypic 
information obtained from home-brew or commercially obtained sequences. Such sites may be useful 
for  updated  analysis  of  genotypes  obtained  5–10  years  ago  that  were  originally  interpreted  with  
older algorithms. 
In  addition to reporting resistance identification, HIV drug resistance reports offer a wealth of 
additional useful information, particularly when combined with clinical information; five examples 
illustrate clinical utility of careful evaluation of genotypic data. First and most obviously, the absence 
of any drug resistance mutations, in the setting of high rebound viremia strongly suggests adherence 
issues may be the cause of rebound viremia. Second, the emergence or loss of certain drug resistance 
mutations responds relatively rapidly to the presence of the antiretroviral drug pressure. Resistance to 
3TC or  FTC is  typically  accompanied by the mutation M184V; M184I also confers resistance to 
cytidine analogues, but is usually only transiently detected, if at all, early during therapy with 3TC or 
FTC. M184I is rapidly outcompeted by the M184V mutation. As a result, the presence of the M184I 
mutation suggests that individuals have recently initiated (or re-initiated) therapy with 3TC. M184V 
itself responds relatively rapidly to the presence of 3TC; loss of this mutation during therapy with 3TC 
raises adherence concerns. Third, the presence of polymorphisms at resistance sites may be a useful 
observation. The presence of polymorphisms at sites strongly selected by the regimen (e.g., M41M/L, 
during AZT therapy) suggests that drug selection pressure has not been uniform, and non-adherence 
may play a role in rebound viremia. Fourth, genetic analysis and detecting the presence of uncommon 
mutations may offer useful insight into the origin of the infection in an individual. Genotypic analysis 
is  used  to  determine  HIV  subtype;  non-B  subtypes  are  readily  detected  by  this  method,  and  can 
provide useful information regarding geographic source of infection. Uncommon mutations at position 
215 of reverse transcriptase, such as T215S, T215C, reflect back mutations [44], suggest the prior 
presence of T215Y or F, and often represent strong evidence of transmitted drug resistance. Finally, 
some resistance sites are reported to confer resistance to one antiretroviral and may confer increased 
sensitivity to other antiretroviral drugs. Examples include K65R, which confers high level resistance to 
tenofovir, confers increased sensitivity to AZT; the mutation T215Y confers resistance to AZT, but is 
more sensitive to tenofovir than the wild type T215. Clinical correlates of these in vitro observations 
are uncertain but may be useful in constructing new regimens to treat the resistant virus [45]. 
2.1.2. Phenotyping 
Genotyping information may yield complex mutational patterns. Phenotyping assays have been 
developed in an effort to provide a functional evaluation of patient derived HIV-1 protease and reverse 
transcriptase.  Recombinant  DNA  technology  [46]  generating  chimeric  plasmids  with  gag/pol 
sequences  from  patient  isolates  cloned  into  laboratory-adapted  HIV-1  strains  permits  reliable  and Viruses 2011, 3                         
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reproducible measurement of in vitro resistance; several assays are commonly available using different 
strategies as single round or multiple round infections [35,47,48] (Figure 1A). HIV-1 protease, RT, 
integrase,  and  envelope  sequences  amplified  from  patient  material  using  RT-PCR  techniques  as 
described above for genotyping are introduced into a recombinant molecular clone of HIV-1, either by 
direct ligation, or by simply mixing and allowing ligation to occur during the transfection [49]. Virions 
produced  by  transfection  are  standardized  and  used  to  inoculate  cultures  of  susceptible  cells  
(Figure 1B); in parallel, cultures are inoculated with wild type virus. Infections are carried out in the 
presence of increasing concentrations of individual antiviral agents, viral replication measured and 
dose  response  curves  constructed  (see  Figure  1C);  the  concentration  of  drug  necessary  for  50% 
inhibition of virus replication is reported as IC50. Conceptually, the two approaches appear to offer 
different advantages. Single round assays eliminate the possibility that resistance may arise during the 
cultivation of wild type virus in the presence of the drug [50]. Multi-round cultivation assays may 
detect low level resistance that may not manifest in a single round assay. Direct comparison of these 
two assays revealed remarkably concordant results [51]. 
Both phenotyping systems evaluate only a portion of patient derived material; any interactions 
between  portions  of  HIV  genome  from  patient  derived  virus  are  not  measured.  For  example, 
phenotypic analysis of patient derived HIV protease takes place without inclusion of most protease 
cleavage sites as additional compensatory changes may occur at cleavage sites, it is likely that a degree 
of phenotypic information is lost in the process [52–54]. New phenotypic assays have been developed 
to  investigate  HIV  tropism  to  evaluate  patients  who  are  under  consideration  for  therapy  with 
coreceptor inhibitors. Such assays are can detect the presence of X4 or dual X4/R5 tropic virus at low 
levels and are recommended prior to drug initiation, as the presence of X4 or dualtropic virus is likely 
not to be susceptible to coreceptor inhibitors in viremic patients [35].  
Increases  in  IC50  are  associated  with  drug  resistance,  but  the  degree  of  virologic  resistance 
associated with clinical drug failure is not clear in all circumstances. Establishment of effective cutoffs 
has been a major effort in phenotyping development. For some antiretrovirals, such as efavirenz or 
3TC, large increases in IC50 are noted, and identifying resistance is straightforward. In contrast, drugs 
such as ddI or d4T have a more restricted dynamic range in phenotyping assays. Phenotypic sensitivity 
scores were predictive of viral RNA responses in treatment experienced patients initiating protease 
inhibitor regimens [55], demonstrating the utility of phenotypic results and RNA responses, but precise 
cutoffs are relatively difficult to assign. One approach has been to evaluate the distribution of drug 
resistance in isolates from drug naïve individuals and assigning cutoffs at IC50 levels several standard 
deviations beyond the mean drug naïve level [56]. Use of clinical trial and cohort analysis has also 
been proposed to estimate clinical cutoffs [57]. Increasing knowledge regarding the nature of drug 
resistance  and  the  success  of  commercial  drug  resistance  testing  has  permitted  analysis  of  large 
numbers of matched HIV genotypes and phenotypes and development of bioinformatics tools that 
predict phenotypic responses based solely on genotypic information. These analyses have been studied 
in clinical trials and are commercially available [58–60] or open access [61] e.g., [62]or ANRS [63] 
and  Rega  algorithms  [64]  and  the  Stanford  HIVDB  [43]  are  generally  well  correlated  with 
experimental phenotypic drug resistance data and have recently been reviewed [65,66]. A current list 
of resistance mutations is maintained and updated regularly [67].  Viruses 2011, 3                         
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Figure  1. HIV Phenotyping of HIV protease (PRO), RT, integrase (IN) in Cell Based 
Assays. (A) Schematic of sample processing from phlebotomy to construction of chimeric 
recombinant plasmids composed of patient derived sequences in standard laboratory based 
HIV standard clones. Single round assays use HIV derivatives encoding a reporter gene 
instead  of  HIV  env.  Upon  transfection  into  producer  cells  expressing  a  helper  virus 
envelope, virions are produced which can undergo a single round of replication. Multiple 
round  assays  introduce  patient-derived  material  into  standard  laboratory  HIV,  and 
recombinant plasmids transfected into producer cells. (B) Virions produced by transfection 
are standardized and used to infect susceptible cells. In single round assays, pseudo typed 
viruses  undergo  reverse  transcription  and  integration,  but  are  unable  to  propagate. 
Production of reporter gene product (e.g., luciferase, green fluorescent protein) denotes 
successful  round  of  replication.  In  multiple  round  infections,  virus  is  inoculated  and 
production  measured  by  standardized  measures,  typically  production  of  p24  antigen  in 
media.  (C)  To  determine  phenotypic  response  to  antivirals,  virus  is  inoculated  in  the 
presence of increasing concentrations of single antiretrovirals. Dose response curves are 
constructed and measure of drug inhibition; the amount of drug necessary to inhibit 50% of 
virus replication (IC50) is calculated. Adapted from [68]. 
 Viruses 2011, 3                         
 
 
354 
Figure 1. Cont. 
 
 
Direct  comparisons  of  virtual  phenotypic  data  with  genotype  and  phenotype  have  not  been 
extensively investigated. In the CREST trial, Emrey and colleagues [69] did not detect a difference in 
virologic success in a randomized study of individuals undergoing drug resistance testing with or 
without virtual phenotyping; Saracino and coworkers obtained similar virologic suppression in patients 
using virtual or real phenotypic results [59]. A number of research approaches have incorporated IC50 
phenotypic data with levels of drug measured in individual patients. These inhibitory quotients have 
correlated  well  with  drug  suppression  [70,71],  but  have  not  been  used  extensively  yet  in  routine 
clinical practice. Viruses 2011, 3                         
 
 
355 
An entirely new analysis of phenotypic data derives new and useful information from slopes of the 
dose response curve [72] used to determine instantaneous inhibitory potentials. Dose response slopes 
were found to be class specific, and these authors established limits for the  inhibitory activity of 
individual  drugs  and  for  entire  classes.  In  this  analysis,  NNRTIs  and  protease  inhibitors  had  the 
greatest  activity  against  wild  type  virus.  The  performance  characteristics  of  the  instantaneous 
inhibitory potential have not yet been field tested in detail or with drug resistant virus. An initial 
analysis by Kuritzkes and colleagues obtained similar outcome data using IIP or IQ, and the clinical 
utility of these modalities remains under study [73]. 
3. Clinical Utility of Drug Resistance Testing 
3.1. Evidence Base for the Use of Drug Resistance Assays in Clinical Management of HIV-1 Infection 
A  number  of  randomized,  prospective  studies  investigated  the  utility  of  resistance  testing  in 
management of antiretrovirals [74–78]. VIRADAPT [79] and GART [80] were two early prospective 
genotyping studies that randomized patients to two arms: genotyping and standard of care. The benefit 
in both of these trials appeared to be the ability of genotyping to identify a greater number of active 
antiretrovirals. VIRA3001 [75] was a randomized study comparing phenotyping and standard of care 
in 272 viremic patients; at the week 16 endpoint phenotyping arm had demonstrated a greater effect on 
reducing HIV-1 viremia measured by proportion of patients <400 c/mL; in the secondary analysis, 
phenotyping was also superior to SOC in reducing viremia, measured by area under the curve minus 
baseline. The specific benefit of additional “expert advice” e.g., panels of investigators with extensive 
experience in HIV therapy was specifically investigated in HAVANA [78], a factorial design study 
comparing  both  the  use  of  genotyping  and  the  use  of  expert  advice  in  virologic  outcome  
(VL < 400 c/mL). Genotyping was superior to no genotyping even in the absence of expert advice, 
using only the algorithm interpretation of the genotype. In addition, expert advice was beneficial even 
in  the  absence  of  genotyping;  more  recently,  higher  agreement  rates  among  those  with  “expert 
opinion” suggests more consensus among therapeutic options [81]. 
Duration of these studies were relatively short; ARGENTA was a prospective randomized study 
comparing efficacy of genotyping and standard of care at two time points [76] in reducing viral loads. 
Although the proportion of patients suppressed <500 c/mL was significantly greater in the genotyping 
arm after 12 weeks, the effect was not sustained and no benefit of genotyping was detected at 24 
weeks. The durability of resistance testing beyond one year has not been studied prospectively. Many 
of the studies were performed prior to widespread use of sensitive <50 copy limit assays and used 
<400 c/mL or <500 c/mL as a measure of success; it is not clear whether all successful treatments 
reached the more stringent measure of suppression, but the virologic benefit realized in genotyping 
arm of the ARGENTA was persistent in subsequent longitudinal analysis [76]. 
Several trials have not demonstrated benefit of resistance testing. NARVAL was a randomized 
study of phenotyping, genotyping and standard of care [77] no benefit of resistance testing was noted 
in the entire cohort; in a sub analysis of patients a benefit of genotyping in patients with a single prior 
PI-containing regimen was detected. NARVAL patients were in general more drug experienced than in 
prior trials, and the absence of effective drugs regardless of resistance testing may have contributed to 
the equal success rates. NARVAL was initiated after resistance testing had been generally introduced, Viruses 2011, 3                         
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and  physicians  had  the  benefit  of  earlier  trials  of  the  performance  of  antivirals  in  various  drug 
resistance settings. 
In these early studies, participants were generally less antiviral experienced than patients currently 
failing therapy. The clinical benefit of resistance testing in viral suppression in highly experienced 
patients has not been extensively investigated. In NARVAL [77], no significant differences in adverse 
event reporting were detected in resistance testing and standard of care arms. The CCTG575 Study of 
238 patients with drug resistance did not demonstrate a clear benefit of phenotyping over standard of 
care, although benefits were noted in patients with more resistant virus [82]. A meta analysis of the 
effectiveness of drug resistance testing of ten trials highlighted the short term nature of the benefits of 
genotyping and virtual phenotyping  [83]. In contrast, retrospective analysis of 2699 of the HOPS 
natural  history  cohort  study  patients  over  the  period  1999–2005  revealed  a  survival  advantage  in 
management of drug  resistance  that  included drug  resistance testing compared with expert advice 
alone [84]. Drug resistance testing has become part of the standard of care of individuals with rebound 
viremia  and  remains  recommended  by  guidelines  for  treatment  of  HIV  infected  individuals  [85]. 
Resistance testing is recommended in the initial evaluation of HIV–infected individuals at the time of 
diagnosis, in order to identify individuals with transmitted drug resistance and at confirmed rebound in 
viremia [85,86]. 
4. Drug Class Specific Issues 
4.1. NRTI 
Reverse transcriptase is the central enzyme in HIV replication and mediates RNA-dependent DNA 
synthesis,  RNase  H  excision  of  HIV  RNA  from  RNA:  DNA  hybrid,  and  DNA  directed  DNA 
synthesis. A reverse, “excision” reaction, which removes incorporated nucleotides, also occurs at a 
low rate compared to polymerization. RT assembles as a dimer of p66 and p51 subunits; like a number 
of DNA polymerases, the structure of RT is similar to a right hand, and includes a palm, fingers, and 
thumb  domains  [87]. Nucleoside and  nucleotide reverse  transcriptase  inhibitors  (NRTIs)  represent 
strong inhibitors of reverse transcriptase and inhibit polymerization by chain termination. NRTIs such 
as AZT, 3TC, and ddI represent some of the oldest antiretrovirals, and many individuals with long 
antiretroviral  experience  have  had  extensive  exposure  to  NRTIs  singly  or  in  combination,  with 
accumulation of a number of drug resistance mutations (Figure 2). In general, mutations, result in 
steric effects on drug access, e.g., M184V, 3TC, ddC [88], or kinetic effects that result in marked 
increase in excision of incorporated analogues [89]; thymidine associated mutations (TAMs, including 
M41L,  D67N,  K70R,  L210W,  T215Y/F,  K219Q)  confer  resistance  by  enhanced  excision.  TAMs 
excision may be reduced by M184V. In addition, M184V-containing virus is less fit than wild type 
virus [90,91], perhaps providing an additional virologic benefit. Accumulation of TAMS results in 
increasing resistance to AZT, tenofovir, D4T, abacavir, and ddI. Two multidrug resistance mutation 
profiles in general, confer high level drug resistance to all NRTIs. The Q151M suite of mutations 
(Figure  2)  results  in  selective  decreased  binding  of  NRTI  triphosphate  and  a  degree  of increased 
excision [92,93] ; although tenofovir has some reported activity in this setting [94], while other NRTIs 
such as AZT, D4T, ddI, and abacavir are uniformly ineffective. Insertions following the threonine Viruses 2011, 3                         
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residue at position 69, typically consisting of 1–4 additional residues result in uniformly high level 
resistance to all NRTIs. 
Figure  2.  Mutations  conferring  resistance  to  nucleotide  reverse  transcriptase  inhibitors 
(NRTIs)  are  depicted;  multidrug  resistance  profile  (Q151  complex)  is  indicated  and 
thymidine associated mutations (TAMS) are noted. 
 
Accumulation  of  drug  resistance  mutations  reduces  the  rate  of  reverse  transcription.  RNase  H 
activity of RT, which removes RNA from the RNA:DNA product of first round reverse transcription 
must  work  in  concert  with  polymerization.  Pathak  and  coworkers  hypothesized  that  additional 
mutations  affecting  RNase  H  activity  may  compensate  for  accumulated  mutations  slowing  RT 
mediated  polymerization  [95].  Such  resistance  mutations  have  been  identified  in  the  connection 
domain  of  reverse  transcriptase  [95–97].  Although  this  region  of  RT  is  not  typically  included  in 
commercial genotyping, connection domain mutations may increase resistance to certain NRTIs, such 
as AZT, by 10–100 fold [35,96,97]. The clinical consequences of these new NRTI resistance mutations 
remain under intense study. 
4.2. NNRTI 
NNRTIs bind to a common hydrophobic pocket in the palm domain of RT that is near, but not at 
the HIV RT catalytic site (Figure 3A). Mutations conferring resistance result in changes in binding 
characteristics for the inhibitors [98]. In general, there is extensive cross-resistance among NNRTIs 
(Figure 3B). The majority of NNRTI resistance mutations do not significantly reduce the replication 
capacity  of  HIV,  and  tend  to  persist  for  prolonged  periods.  The  newest  NNRTI,  etravirine,  has 
significant antiviral activity even in the setting of a number of NNRTI resistance mutations, including 
K103N and Y188C. As a result it is possible to construct NNRTI-based regimens in individuals with 
NNRTI resistance. One challenging aspect of such a strategy is ensuring that etravirine mutations 
(Y181C) are not present in individuals, some of whom may have remotely taken NNRTI. It is not  
clear  that  relying  on  population-based  based  genotypes,  which  only  report  on  contemporary  and Viruses 2011, 3                         
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predominant  HIV  sequences,  will  provide  sufficient  sensitivity  to  rule  out  the  presence  of 
concerning mutations. 
Figure 3. (A) Crystal structure of HIV reverse transcriptase p66/p561 dimer is depicted 
with  locations  of  four  common  NNRTI  resistance  mutations  in  a  hydrophobic  pocket 
within the palm domain noted in yellow. Mutations change the binding characteristics of 
NNRTI, explaining cross resistance of nevirapine, delavirdine, and efavirenz. Structural 
data are from [99] and are displayed using RASMOL [100,101]. (B) Mutations conferring 
resistance to individual NNRTIs. Despite some cross resistance, etravirine has antiviral 
activity even in the presence of a number of mutations conferring resistance to nevirapine 
and efavirenz. 
A 
 
B 
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Several studies have demonstrated new RT mutations accumulating on NRTI that confer increased 
susceptibility  to  reverse  transcriptase  [102–104].  The  mechanism  by  which  new  mutations  confer 
hypersusceptibility to NNRTI is uncertain. Hypersusceptibility may affect nucleotide selectivity or 
virus replication capacity [105,106]. Clinical advantage of NNRTI hypersusceptibility has not been 
extensively investigated, but patients with hypersusceptibility did experience higher reductions in viral 
RNA, suggesting a clinical advantage [103,107]. 
4.3. Protease 
HIV protease processes the Gag and Gag/Pol protein precursors, resulting in virus maturation and 
virus infectivity. Protease inhibitors, either peptidometic or nonpeptidometic, are designed to bind to 
the active site of the protease. Protease is only 99 amino acids in length, but tolerates a relatively large 
number of mutations that confer resistance (Figure 4A). A substrate fit model developed by Schiffer 
and colleagues has developed a useful model explaining drug resistance mutations that emerge near 
the active site and in flap domains of the molecule that provide access to the active site [108–110]. In 
general, mutations conferring resistance (Figure 4B) are divided into primary mutations, generally 
drug specific, and secondary mutations, which by themselves confer little resistance to therapy, but in 
the  presence  of  primary  mutations  result  in  increased  cross  resistance  to  a  number  of  protease 
inhibitors [111,112]. Thus, switching protease inhibitors carries a measure of phenotypic “baggage” 
that can affect subsequent protease inhibitor therapy. Additional mutations occur at protease cleavage 
sites, resulting in increased efficiency of cleavage despite accumulation of changes in the enzyme 
proper. Ritonavir is a potent inhibitor of the cyp3A4 metabolic pathway metabolizing many protease 
inhibitors, and the use of ritonavir to pharmacologically boost protease inhibitor levels in patients has 
been a useful strategy to maintain protease inhibitor levels and permit once daily dosing. New agents 
with similar activity are under consideration, including one in clinical trials [113]. 
Figure 4. (A) Crystal structure of HIV protease depicting active site residues (yellow) and 
a series of residues conferring resistance near the active site or at flap domains (circled). 
Structural data are from [114] and are displayed using RASMOL [100,101]. (B) Chart 
depicting resistance to HIV-1 protease. 
A 
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Figure 4. Cont. 
B 
 
4.4. Coreceptor Inhibitors 
Maraviroc inhibits binding of HIV gp120 to the CCR5 coreceptor of HIV. As HIV variants may 
utilize either CCR5 or CXCR4 (or both, “dualtropic” viruses) as coreceptor, resistance to Maraviroc 
may occur as a population shift to CXCR4-tropic or dual tropic viruses. Sensitive tropism assays are 
available  to  determine  presence  of  CXCR4  or  dual  tropic  viruses  at  relatively  low  frequencies 
(reported at 0.1%) [115]. Such tropism assays are required prior to initiating therapy, as the presence 
of dual tropic or CXCR4 tropic virus compromises Maraviroc efficacy. In addition, resistance can 
occur by emergence of mutations that affect binding of Maraviroc. Thus, the etiology of rebound 
viremia on Maraviroc or other coreceptor inhibitors may be multifactorial. 
4.5. Fusion Inhibitors 
Enfuvirtide [116] is a 36 amino acid peptide that binds to alpha helix within gp41, disrupting the 
“spring-loaded”  like  mechanism  that  mediates  viral-cell  fusion  [116,117].  Early  studies  identified 
mutations emerging in the binding domain abrogating enfuvirtide activity, and found such changes in 
great majority of patients with rebound viremia while adherent on enfuvirtide therapy [118,119]. Thus 
it is typically not cost effective to genotype rebound viremia for T-20 resistance mutations. Deeks and 
coworkers demonstrated continued T-20 antiviral activity even in the presence of mutations [120]. It is Viruses 2011, 3                         
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likely  that  drug  resistance  mutations  reduce  replication  capacity;  the  potential  clinical  benefit  of 
maintaining T-20 despite resistance is weighed against the inconvenience, discomfort, and relative 
difficulty in twice daily subcutaneous administration. 
4.6. Integrase Inhibitors 
Raltegravir is the first in class integrase strand transfer inhibitors (INSTI) and represents a highly 
potent  and  well  tolerated  addition  to  the  antiviral  armamentarium  [121–123].  A  second  INSTI, 
elvitegravir, is currently in late stage development  [124]. Despite the marked activity and ease of 
tolerability, raltegravir is, however, similar to all antiretrovirals in that resistance can emerge relatively 
quickly  if  the  drug  is  used  in  combinations  with  ineffective  or  recycled  antivirals.  A  number  of 
independent  pathways  to  resistance  have  been  identified,  with  mutations  at  positions  N155H, 
Q148H/R/K,  or  Y143R/H/C  yielding  high  level  resistance  to  therapy,  typically  with  a  number  of 
additional secondary mutations [125]. Mutations map near the binding site of the inhibitor (Figure 5), 
and  a  common  binding  site  for  raltegravir  and  elvitegravir  explains,  in  part,  the  cross-resistance 
between these two inhibitors [126]. Additional INSTI are in development, at least one of which has 
reported to have some evidence of non-cross resistance to raltegravir [127]. Phenotyping for INSTI are 
now commercially available. 
Figure  5.  Crystal structure of human foamy virus integrase (similar to HIV integrase) 
complexed with DNA substrate, noting the positions of resistance mutations 143, 148, and 
155 relative to the binding site for raltegravir and elvitegravir, and proximity to DNA. 
Structure is from Cherapenov and coworkers [128] and rendered in RASMOL [100,101]. 
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5. Non-Subtype B and HIV-2 Infections 
5.1. Non-Subtype B Infection 
Although  the  vast  majority  of  genotypic  information  has  been  obtained  using  HIV  group  M, 
subtype  B,  investigations  of  non-B  viruses  are  ongoing  and  increasing  [129,130].  A  number  of 
differences  in  drug  resistance  have  been  reported  [131];  for  example  the  rate  in  which  certain 
mutations occur, e.g., K65R appears to occur in subtype C faster than in subtype B [130], and the 
NNRTI drug resistance mutation V106M is commonly identified in subtype C but not B [132,133]; the 
emergence of either mutation may be explained, in part by the baseline wild- type sequence favoring 
the development of the mutation. In general, however, non-B subtypes have similar sensitivities and 
responses to antiretrovirals as subtype B [134–138]. Non-M viruses have not been extensively studied, 
although group O viruses are intrinsically resistant to the NNRTI nevirapine and efavirenz. Initial data 
on etravirine [139] and raltegravir [140] resistance in non-B viruses has been reported. 
5.2. HIV-2 Infection 
HIV-2  infection  shows  striking  differences  in  drug  sensitivity  from  HIV-1.  Although  some 
variability among isolates exists, HIV-2 is intrinsically resistant to NNRTIs; susceptibility to etravirine 
has not been studied extensively. NRTI resistance emerges in HIV-2, and has a higher prevalence of 
multidrug resistance Q151M suite of mutations (A62V, V75I, F77L, F116Y, Q151M) [141,142]. 
6. Clinical Management of Drug Resistance 
Clinical management of HIV drug resistance proceeds as with other clinical diseases, and begins 
with a comprehensive history, followed by physical examination and indicated laboratory studies. In 
general,  patients  undergoing  successful  combination  antiretroviral  therapy  have  viral  RNA  levels 
suppressed below the commercial limit of detection (50–75 copies HIV-1 RNA/mL plasma) using 
either bDNA or RT-PCR based methodologies. 
The first indication that drug resistance may be present is an increase in plasma viremia above the 
clinical cutoff during a routine clinical visit. The turnaround time for HIV RNA levels determination is 
at least several days, and results from testing will not be available if the clinical visit is timed with the 
phlebotomy for HIV RNA. One approach to this delay from phlebotomy to result is to obtain blood for 
viral RNA levels, and CD4 cell numbers one week prior to the clinical visit, at which time the clinical 
evaluation with all relevant laboratories studies may be obtained. In this way, the patient with rebound 
viremia may be counseled in person from the outset. 
All increases in viremia should be evaluated as soon as possible, but not all increases in viremia 
represent drug resistance and other causes are typically ruled out prior to in depth evaluation for 
resistance, and repeat viral RNA testing is essential. Low level increases in viremia (blips, viral RNA 
50-ca. 200 copies HIV RNA/mL plasma) may be the result of assay variation, and do not often reflect 
true  rebound  viremia  [143].  Recent  development  of  a  new  version  of  the  Abbott  amplicor  PCR 
increases in viral RNA have been noted in the 74–200 copy range [144–146]. These increases have not 
been sustained or associated with resistance [147] and may reflect statistical variation near the limit of Viruses 2011, 3                         
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detection. Intercurrent, typically febrile, illnesses represent a second cause of rebound viremia. The 
precise cause of increased viremia remains uncertain, as not all illnesses result in elevations in viremia; 
rebounds that do occur are not associated with drug resistance, and may be the result of generalized 
immune  activation.  A  third  cause  of  rebound  viremia  not  due  to  drug  resistance  is  antiretroviral 
nonadherence.  A  thorough  history  and  physical  examination,  to  rule  out  antecedent  illness  or 
nonadherence  coupled  with  repeat  viral  RNA  testing  represents  the  initial  evaluation  of 
rebound viremia. 
Sustained increases in HIV viremia in the absence of other potential causes suggests that resistance 
mutations conferring drug resistance have emerged. Low level rebound viremia typically continues to 
increase, which prompts resistance testing. A minimum of viremia is essential for resistance testing; 
there  are  no  absolute  limits  although  levels  ca.  500  copies/mL  may  be  unreliably  amplified,  and 
tropism testing requires viremia in excess of 1000 copies/mL plasma. It is difficult to predict which 
component of drug regimen resistance may have failed during rebound viremia. In general, resistance 
mutations that confer high level resistance (e.g., K103N, efavirenz or M184V, 3TC/FTC) are likely to 
be present during rebound viremia. Resistance to other antiretrovirals is more difficult to predict. In 
addition,  as  described  above,  understanding  of  specific  drug  resistance  mutations  that  emerge  on 
therapy  to  specific  agents  may  provide  some  virologic  benefit  in  the  setting  of  other  agents.  For 
instance, development of M184V during 3TC/FTC therapy results in a less fit virus, and one which, in 
the presence of TAMS, is more sensitive to NRTI therapy with AZT, D4T, or tenofovir. Similarly, 
K65R-containing virus arising from from tenofovir, abacavir or ddI is more sensitive to AZT than the 
wild type virus [45,148], T215Y/F-containing virus from AZT therapy is more sensitive to tenofovir 
than wild type virus. As a consequence, 3TC or FTC is often continued in individuals with M184V 
because of the potential antiviral effect. Tenofovir and AZT have been used in treatment experienced 
individuals to suppress T215Y/F and K65R. The results of these laboratory tests represent useful data, 
but are not themselves designed to be clinical management tools. Choice of therapy for treatment 
experienced  individuals  represents  a  cooperative  interaction  between  patients  and  health  care 
professionals and requires assessment of resistance, drug tolerability, adverse effect profile of potential 
agents, and drug interactions. Regimens are often constructed around development of newly developed 
agents directed against novel viral targets, but without additional active agents, the new regimen is 
effectively monotherapy; viral suppression is typically transient and efficacy from the new drug may 
be completely lost. In general, two new agents to which the patient does not have resistance are used 
for therapy for experienced patients [85]. With extensive cross resistance among drug classes, the goal 
of reducing viremia to <50 copies/mL plasma with two fully active agents, is often not possible. 
Despite  adverse  effects,  partially  active  therapy  is  clearly  superior  to  drug  interruptions;  useful 
guidelines are available to assist antiretroviral choice [85,86]. 
As described, therapy for HIV infection is individualized based on firm basic and clinical science. 
Guidelines for the use of antiretroviral therapy have been developed and are regularly updated; panels 
of experts review and debate accumulated evidence and provide recommendations regarding use of 
antiretrovirals and resistance testing. Several commendable aspects of this process include: Graded 
recommendations, e.g., critical recommendations well founded by randomized controlled trials are 
weighted with high confidence. Recommendations that are based on “expert opinion” are marked with 
lower confidence. In addition, some guidelines include a highlighted discussion of new or changed Viruses 2011, 3                         
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recommendations, providing knowledgeable practitioners with a rapid mechanism to update their fund 
of knowledge. The US Department of Health and Human Services guidelines is regularly updated in a 
“living-document” fashion [149]. As a consequence, providers worldwide have access to current and 
useful information. 
7. Unresolved Issues 
Although  several  clear  instances  of  pre-existing  mutations  contributes  to  emergence  of  drug 
resistance, not all resistance is clearly explained by pre-existing resistance mutations, and the role of 
low  level  drug  resistance  mutations  remains  undefined.  Genetic  composition  of  HIV  from  drug 
resistant individuals is complex but can be investigated with sensitive techniques [13,14,150–153]. In 
one sense, since most of single drug resistance mutations are likely present in large genetically diverse 
virus populations [10,154], the real question is what level of resistance is associated with clinical 
resistance [155]. Cross-sectional studies of low level transmitted drug resistance was associated with 
regimen failure [156,157], and recent analysis of ACTG5095 [158] demonstrated increased risk of 
regimen  failure  in  the  presence  of  low  level  NNRTI  mutations,  and  analysis  of  ACTG5208, 
randomized  study  of  combination  therapy  for  individuals  with  prior  nevirapine  exposure  revealed 
relatively  low  level  resistance  [159]  was  associated  with  risk  of  viral  rebound  or  death  [160]. 
Application of new techniques, such as massively parallel pyrosequencing, may shed new light on the 
role of minority resistance or tropism variants in emergence of HIV drug resistance [161–164]. 
Viral  rebound  or  viral  suppression  may  occur  [165]  in  the  presence  of  a  partially  suppressive 
regimen. For instance, patients taking NNRTI based regimens may experience viral rebound; analysis 
of drug resistance may reveal emergence of a single nucleotide change conferring drug resistance [11]. 
Continued suppression; however, may also occur in the presence of a single mutation such as K103N. 
Why viremia rebounds in some patients but not others with known mutations is unknown. 
The relative contributions of individual antiretroviral during rebound viremia remains uncertain, but 
such data might be most useful in constructing new regimens. Whether some drugs (e.g., tenofovir, 
protease  inhibitors,  INSTI)  continue  to  have  efficacy  in  the  setting  of  accumulated  resistance 
mutations  has  not  been  well  described.  Contributions  of  HIV  fitness  to  viral  replication  and 
pathogenesis, reviewed in [166] are clear. Sensitive viral fitness assays are useful in understanding the 
effects of mutations on viral replication and pathogenesis [167–170], and in understanding replication 
of viruses from individuals [171] but are not feasible for routine clinical use. Relative replication 
capacity measurements are made in some phenotyping assays. When fully suppressive regimens are 
not possible, choosing regimens yielding lowest replication capacity may be desirable; in early studies, 
higher CD4 cell numbers were associated with lower replication capacity [172,173], and accumulation 
of  drug  resistance  mutations  is  associated  with  lower replication  capacity  [125,173,174] but  clear 
evidence for clinical benefit of lower relative replication capacity remains under study. 
New  bioinformatics  approaches  to  analyze  genotypic  and  phenotypic  data  continue  to  be 
investigated [72]. In general, resistance testing analyzes individual drugs singly, not in combination. 
New  artificial  neural  networks  are  in  development  that  incorporate  resistance  data  with  clinical 
information  to  identify  entire  regimens  in  a  patient  specific  manner  [175–177].  The  use  of 
induction-maintenance  therapeutic  strategies  has  resulted  in  persistent  suppression  for  prolonged Viruses 2011, 3                         
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periods [159,178,179], but how a single agent maintains suppression in a substantial proportion of 
patients remains uncertain. Continued studies of population dynamics and the potential contribution of 
immune responses are likely to shed new light on the nature of drug resistance in vivo. 
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